For Bisphosphonate Therapy, Longer Is Not Necessarily Better.

[Argirios Argiriou]

SUMMARY AND COMMENT | WOMEN'S HEALTH, GENERAL MEDICINE

October 12, 2017

For Bisphosphonate Therapy, Longer Is Not Necessarily Better
 

Andrew M. Kaunitz, MD reviewing Drieling RL et al. J Am Geriatr Soc 2017 Sep .


Data from the WHI provide guidance about optimal duration of use.

Although bisphosphonates' efficacy in preventing fragility fractures is well established, questions persist about optimal duration of use. Some 97,000 participants in the Women's Health Initiative (WHI) observational and randomized trials completed medication forms. Among a subgroup of 5120 women (mean age, 80; 94% white) with estimated 5-year hip fracture risk ≥1.5% and ≥2 years of self-reported bisphosphonate use, investigators assessed risk for incident fractures following various durations of bisphosphonate therapy (2 years, 3–5 years, 6–9 years, and 10–13 years).

During additional mean follow-up of 3.7 years, fracture rates were 2% for hip fractures, 3% for radius or forearm fractures, 5% for clinical vertebral fractures, and 26% for any clinical fracture. Adjusted analysis showed that, compared with 2 years of bisphosphonate use, 10 to 13 years of use was associated with a modestly but statistically significantly higher risk for any clinical fracture (hazard ratio, 1.29; 95% confidence interval, 1.07–1.57). Risks after 10 to 13 years of use were even higher for hip fractures (HR, 1.66) and clinical vertebral fractures (HR, 1.65), although these did not reach statistical significance, possibly because of the small numbers in these subgroups. Compared with 2 years' use, 3 to 5 and 6 to 9 years' use did not confer excess fracture risk overall or at specific sites.
 



Comment

This study — the largest to assess fracture risk in older, female, long-term bisphosphonate users — supports discontinuing therapy after 2 to 5 years. As an editorialist notes, whether (and when) to restart bisphosphonate therapy after a drug holiday depends on which agent has been used and the patient's underlying fracture risk.
 
 

Editor Disclosures at Time of Publication

Disclosures for Andrew M. Kaunitz, MD at time of publication


Consultant / Advisory board
 
Allergan; Bayer AG; Merck; Mithra; Pfizer; Shionogi
 

Royalties
 
UpToDate
 

Grant / Research support
 
Therapeutics MD; Bayer; Agile; Merck; Millendo; Mithra
 

Editorial boards
 
Contraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health
 

Leadership positions in professional societies
 
North American Menopause Society (Board of Trustees)
 
 

Citation(s):


Drieling RL et al. Long-term oral bisphosphonate therapy and fractures in older women: The Women's Health Initiative. J Am Geriatr Soc 2017 Sep; 65:1924. (Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος)
 

Lyles KW.Have we learned how to use bisphosphonates yet? J Am Geriatr Soc 2017 Sep; 65:1902. (Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος)
 
 
Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος